CytomX shares rose 2.3%, a roughly flat reaction. The company is advancing Varseta-M, but key evidence—including an overall survival update and a potential registrational strategy—remains pending.
- CytomX plans to move Varseta-M monotherapy toward a potential registrational study in metastatic colorectal cancer in the first half of 2027.
- The company expects an integrated Phase 1 update in January, including the first look at overall survival; it is evaluating 8.6 mg/kg and 10 mg/kg doses every three weeks with adjusted ideal body weight dosing and upfront prophylaxis.
- The Varseta-M plus bevacizumab Phase 1 study continues to enroll late-line CRC patients, with initial clinical data anticipated in the first half of 2027. A separate Phase 1/2 combination study is planned to begin by year-end.
- CytomX has opened early cohorts in gastric and gastroesophageal junction cancer, and in EpCAM-selected pancreatic and biliary tract cancers, initially aiming to enroll about 20 patients per tumor type.
- The transcript excerpt ends during the CX-801 update, so it provides no further detail on that program.
Community Discussion